Primary aldosteronism is the most common form of endocrine hypertension. This disorder comprises both sporadic and familial forms. Four familial forms of primary aldosteronism (FH-I to FH-IV) have been described. FH-III is caused by germline mutations in KCNJ5, encoding the potassium channel Kir3.4 (also called GIRK4). These mutations alter the selectivity filter of the channel and lead to abnormal ion currents with loss of potassium selectivity, sodium influx and consequent increased intracellular calcium that causes excessive aldosterone biosynthesis. To date, eleven families have been reported, carrying six different mutations. Although the clinical features are variable, FH-III patients often display severe hyperaldosteronism with an early onset, associated with hypokalemia and diabetes insipidus-like symptoms. In most cases FH-III patients are resistant to pharmacological therapy and require bilateral adrenalectomy to control symptoms. In the present manuscript, we review the genetics and pathological basis of FH-III, the diagnostic work-up, clinical features and therapeutic management. Finally, we will describe a new case of FH-III of an Italian patient carrying a Gly151Arg mutation.Journal of Human Hypertension advance online publication, 27 April 2017; doi:10.1038/jhh.2017.34.
Familial hyperaldosteronism type III
Monticone, S
First
;Tetti, M;Burrello, J;Buffolo, F;Veglio, F;Williams, TA;Mulatero, P
Last
2017-01-01
Abstract
Primary aldosteronism is the most common form of endocrine hypertension. This disorder comprises both sporadic and familial forms. Four familial forms of primary aldosteronism (FH-I to FH-IV) have been described. FH-III is caused by germline mutations in KCNJ5, encoding the potassium channel Kir3.4 (also called GIRK4). These mutations alter the selectivity filter of the channel and lead to abnormal ion currents with loss of potassium selectivity, sodium influx and consequent increased intracellular calcium that causes excessive aldosterone biosynthesis. To date, eleven families have been reported, carrying six different mutations. Although the clinical features are variable, FH-III patients often display severe hyperaldosteronism with an early onset, associated with hypokalemia and diabetes insipidus-like symptoms. In most cases FH-III patients are resistant to pharmacological therapy and require bilateral adrenalectomy to control symptoms. In the present manuscript, we review the genetics and pathological basis of FH-III, the diagnostic work-up, clinical features and therapeutic management. Finally, we will describe a new case of FH-III of an Italian patient carrying a Gly151Arg mutation.Journal of Human Hypertension advance online publication, 27 April 2017; doi:10.1038/jhh.2017.34.File | Dimensione | Formato | |
---|---|---|---|
Manuscript.docx
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
82.54 kB
Formato
Microsoft Word XML
|
82.54 kB | Microsoft Word XML | Visualizza/Apri |
Table 1. Features of FH-III families.docx
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
19.74 kB
Formato
Microsoft Word XML
|
19.74 kB | Microsoft Word XML | Visualizza/Apri |
Figure 1 - KCNJ5 germline mutations.tif
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
326.61 kB
Formato
TIFF
|
326.61 kB | TIFF | Visualizza/Apri |
Figure 2 - Index case's chromatogram-KCNJ5 G151R.tif
Accesso aperto
Dimensione
192.31 kB
Formato
TIFF
|
192.31 kB | TIFF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.